Vertex Pharma (VRTX) Tops Q2 EPS by 83c
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $510.72 +0.47%
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.11, $0.83 better than the analyst estimate of $2.28. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.72 billion.
GUIDANCE:
Vertex Pharma sees FY2021 revenue of $7.2-7.4 billion, versus the consensus of $6.99 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Endava CFO placed on leave amid accounting probe
- Ledyard Financial Group adds two directors, three retire
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
